JP2024533423A5 - - Google Patents
Info
- Publication number
- JP2024533423A5 JP2024533423A5 JP2024515562A JP2024515562A JP2024533423A5 JP 2024533423 A5 JP2024533423 A5 JP 2024533423A5 JP 2024515562 A JP2024515562 A JP 2024515562A JP 2024515562 A JP2024515562 A JP 2024515562A JP 2024533423 A5 JP2024533423 A5 JP 2024533423A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- use according
- flumonertinib
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/117692 WO2023035223A1 (zh) | 2021-09-10 | 2021-09-10 | 药物组合物及其用途 |
| CNPCT/CN2021/117692 | 2021-09-10 | ||
| PCT/CN2022/086053 WO2023035611A1 (en) | 2021-09-10 | 2022-04-11 | Pharmaceutical composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533423A JP2024533423A (ja) | 2024-09-12 |
| JP2024533423A5 true JP2024533423A5 (https=) | 2025-04-18 |
Family
ID=85507161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515562A Pending JP2024533423A (ja) | 2021-09-10 | 2022-04-11 | 薬学的組成物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240366600A1 (https=) |
| EP (1) | EP4398909A4 (https=) |
| JP (1) | JP2024533423A (https=) |
| KR (1) | KR20240074779A (https=) |
| CN (1) | CN117957000A (https=) |
| AU (1) | AU2022341942A1 (https=) |
| CA (1) | CA3231192A1 (https=) |
| IL (1) | IL311331A (https=) |
| MX (1) | MX2024002822A (https=) |
| WO (2) | WO2023035223A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116159062A (zh) * | 2021-11-24 | 2023-05-26 | 上海艾力斯医药科技股份有限公司 | 药物组合物及其用途 |
| JP2025510910A (ja) * | 2022-03-31 | 2025-04-15 | アストラゼネカ・アクチエボラーグ | 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤 |
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
| CN116478138A (zh) * | 2023-04-21 | 2023-07-25 | 江苏艾力斯生物医药有限公司 | 一种甲磺酸伏美替尼原料药的结晶方法 |
| CN116893086A (zh) * | 2023-04-28 | 2023-10-17 | 江苏艾力斯生物医药有限公司 | 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法 |
| CN117547536A (zh) * | 2023-11-15 | 2024-02-13 | 江苏艾力斯生物医药有限公司 | 一种药物组合物、其制备方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| CN107163026B (zh) * | 2016-03-07 | 2019-07-02 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
| CN110590749B (zh) * | 2016-03-07 | 2020-11-06 | 上海艾力斯医药科技股份有限公司 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
-
2021
- 2021-09-10 WO PCT/CN2021/117692 patent/WO2023035223A1/zh not_active Ceased
-
2022
- 2022-04-11 CN CN202280061191.5A patent/CN117957000A/zh active Pending
- 2022-04-11 WO PCT/CN2022/086053 patent/WO2023035611A1/en not_active Ceased
- 2022-04-11 EP EP22866089.0A patent/EP4398909A4/en active Pending
- 2022-04-11 MX MX2024002822A patent/MX2024002822A/es unknown
- 2022-04-11 JP JP2024515562A patent/JP2024533423A/ja active Pending
- 2022-04-11 AU AU2022341942A patent/AU2022341942A1/en active Pending
- 2022-04-11 KR KR1020247011293A patent/KR20240074779A/ko active Pending
- 2022-04-11 US US18/690,221 patent/US20240366600A1/en active Pending
- 2022-04-11 IL IL311331A patent/IL311331A/en unknown
- 2022-04-11 CA CA3231192A patent/CA3231192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024533423A5 (https=) | ||
| EP1572194B1 (en) | Anti-cancer composition comprising dmxaa | |
| PL187914B1 (pl) | Zastosowanie nikotyny do wytwarzania leku do leczenia zapalnej choroby jelit, preparat farmaceutyczny zawierający nikotynę, kompleks nikotyny i karbomeru i sposób jego wytwarzania | |
| AU2022400308B2 (en) | Cdk4 inhibitor for the treatment of cancer | |
| JP2024539476A5 (https=) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| CN115135649A (zh) | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 | |
| TWI760306B (zh) | 供治療癌症之口服投予紫杉醇及Ｐ-ｇｐ抑制劑的治療性組合 | |
| CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| TW202541803A (zh) | 含有三氟甲基的化合物在治療血液腫瘤中的應用 | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| CN118697745A (zh) | 丹参酮iia制备治疗抗肿瘤药相关心肌病的药物的应用 | |
| CN113453685A (zh) | 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法 | |
| CN118338901A (zh) | 用于治疗癌症的cdk4抑制剂 | |
| CN115135326B (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2024527715A5 (https=) | ||
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| Varveris et al. | Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: a phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung | |
| WO2026092748A1 (zh) | 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌 | |
| RU2024116439A (ru) | Фармацевтическая композиция и ее применение | |
| WO2026021478A1 (zh) | Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法 | |
| Buccheri et al. | Combination Chemotherapy with Methotrexate, Adriamycin, Cyclophosphamide and CCNU (MACC) for Nonsmall Cell Lung Cancer: 4-Year Experience with 92 Patients | |
| Kosaka et al. | Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma | |
| KR101221640B1 (ko) | 자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도 |